News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

North American Scientific Inc. (NASI) Signs Definitive Agreement to Divest Prostate Brachytherapy Product Line


2/12/2009 10:10:22 AM

CHATSWORTH, Calif.--(BUSINESS WIRE)--North American Scientific, Inc. (Nasdaq: NASM) announced today that it has entered into a definitive agreement to sell its prostate brachytherapy product line to Best Theratronics, Ltd., part of the TeamBest Family of Companies. These products currently include Prospera® brachytherapy seeds, SurTRAK™ needles and strands and various accessories used primarily in the treatment of prostate cancer. NASM will receive $5 million for the product line, with $2 million being paid at the closing of the transaction and the remaining $3 million being paid in installments over the 12 month period following the closing.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES